This decision gives patients in the United States an alternative that has been used in millions of patients worldwide for relieving the pain and stiffness associated with the disease. Millions of people are still searching for an effective treatment they can tolerate. For these patients, today s clearance of Mobic tablets for marketing in the U.S. provides an important new option. Mobic tablets will be marketed in the United States jointly by Boehringer Ingelheim Pharmaceuticals, Inc. and Abbott Laboratories. Often, arthritis patients try several medications and find they are not effective or cause side effects that make tolerating the medication difficult.
Some patients keep searching, while others simply give up.
Osteoarthritis can be a very debilitating condition, often diminishing the quality of daily life for people who suffer from it, says Dr. David Yocum, director of the University of Arizona Arthritis Center. Many of these patients cannot be successfully treated with current options, and even the newest choices do not work for everyone. Mobic tablets provide patients with a new alternative when other treatments are discontinued, whether due to lack of efficacy or side effects. The safety and efficacy of Mobic tablets were established through clinical trials involving more than 22,000 patients both here and abroad. In the United States, Mobic tablets are indicated as a once-daily medication for relief of the signs and symptoms of osteoarthritis.